Speaker List - 8th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

8th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

8th - 9th February 2023 | Double Tree by Hilton, San Diego - Mission Valley
CONFERENCE SPEAKERS
Speakers
John Rossi
John Rossi
Vice President, Head, Translational Medicine, ,
Syncopation Lifesciences


John M Rossi is Vice President of Translational Medicine at Syncopation Life Sciences.  John is an experienced Cell Therapy and Biotechnology leader with over 22 years of experience building robust clinical pharmacology, predictive biomarker, and correlative science processes to support oncology drug development. Most recently John was Senior Vice President of Research and Head of Translational Medicine at CERo Therapeutics. At CERo, John helped to guide Research, Process Development and Vector Sciences teams to advance preclinical initiatives. Prior to CERo, John was Senior Director and Head of Clinical Pharmacology at Kite, a Gilead Company. At Kite, John played an instrumental role in supporting global approvals of both Yescarta® and Tecartus® as well as IND approvals to advance investigational autologous T cell therapy products (KITE-363 and KITE-222). Among John’s notable achievements at Kite, he has represented the organization through numerous external scientific presentations and collaborative manuscripts with leading academic researchers in the cell therapy field. Significant scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on functionality and fitness, novel biomarker knowledge helping to elucidate CAR T-cell mechanism of action in humans, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, and the pivotal role of IL-15 in the context of CAR T-cell function. John began his tenure in clinical pharmacology and biomarker development at Amgen in 2002, leading global biomarker development for Phase III registrational trials in oncology (trebananib, AMG386), and preclinical, first-in-human and Phase II clinical trials (AMG780, AMG224 and AMG176). John has co-authored over 35 publications in the field of cell therapy and is co-inventor on 9 issued or submitted patents. John earned his Master of Science degree in Molecular Biology at Portland State University and his B.S. degree in Biology at Pitzer College in Claremont CA.


George Pell
George Pell
CEO and Founder,
Thirty-Six


George Pell is the Principal and Chief Strategy Officer of Thirty-Six, an innovation studio bringing a series of ventures to life for advancing neuroscience, medical intelligence, and human potential. George brings over 20 years from this space, where emerging technologies are first crafted and brought to life, including several which have helped shape the landscape of AI for the life sciences, such as discovery, augmented intelligence, and other cognitive technologies. He has made a multi-billion dollar impact in a range of innovation, strategy, and transformation roles for some of the world’s largest companies in the most high stakes of circumstances. George has invested his most recent 14 years in the life sciences space, where he brings a multidiscipline of advanced biology together with discovery and intelligence technologies, for next-gen applications in neuroscience and precision medicine.


Majid Ghoddusi
Majid Ghoddusi
Senior Director, Clinical Biomarkers,
Poseida Therapeutics


Dr Ghoddusi has over 15 years of experience in some of the most challenging areas of oncology with focus on drug discovery and clinical development. Dr Ghoddusi has broad and overarching insights into unmet therapeutic areas with expertise in translational sciences and clinical biomarker development which allows him to provide unique perspective on how to propel therapeutic projects from discovery to approval. Trained as a translational pathologist he has held numerous positions at large pharmaceutical and small biotech companies including Novartis, Celgene and Juno Therapeutics. His current focus is Gene and Cellular Therapy.


Shannon Muir
Shannon Muir
Co-director of the California Initiative to Advance Precision Medicine in the California Governor’s Office of Planning and Research,



Amy Wehn
Amy Wehn
Director, Companion Diagnostics,
Merck



Heather Cohen
Heather Cohen
Director, Translational Sciences,
Bicycle Therapeutics



Ian Pike
Ian Pike
Chief Scientific Officer,
Proteome Sciences PLC


Ian Pike is the Chief Scientific Officer at Proteome Sciences and has over 30 years’ experience working in the diagnostics and biotechnology sectors. Since joining Proteome Sciences in 2002 he has held a number of roles covering intellectual property management, business development, operational management and is now focused on leading the Company’s scientific strategy to offer clients a flexible, high-quality service.


Anna Katrin Szardenings
Anna Katrin Szardenings
Senior Director, Global Imaging Biomarkers,
Janssen Pharmaceuticals



Senior Representative, EpigenDx
Senior Representative, EpigenDx
,



Maria Wang
Maria Wang
Associate Director,
Bristol-Myers Squibb



Senior Representative, BD Biosciences
Senior Representative, BD Biosciences
,



Huw Davies
Huw Davies
VP, Global Sales,
Owlstone Medical



Desiree Schenk
Desiree Schenk
Principal Scientist,
Gritstone Oncology



Mason Israel
Mason Israel
Regional Medical Affairs Director,
Mirati Therapeutics



Rakesh Dixit
Rakesh Dixit
CEO,
Bionavigen


Rakesh Dixit is a President & CEO, BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. Accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, AstraZeneca.


Michael Milburn
Michael Milburn
President, CEO,
GeneCentric Therapeutics



Yingpeng Zhan
Yingpeng Zhan
Scientist,
Sorrento Therapeutics